Scarica l'app Stockscreener
0.924
2.69%
-0.0255
Precedente Chiudi:
$0.9495
Aprire:
$0.91372
Volume 24 ore:
11,704
Relative Volume:
10.57
Capitalizzazione di mercato:
$N/A
Reddito:
$52.16M
Utile/perdita netta:
$-48.60M
Rapporto P/E:
-0.2139
EPS:
-4.32
Flusso di cassa netto:
$-77.48M
1 W Prestazione:
-2.69%
1M Prestazione:
-30.75%
6M Prestazione:
-56.03%
1 anno Prestazione:
-82.58%
Intervallo 1D:
$0.91
$0.93
Intervallo di 1 settimana:
$0.91
$0.93
Portata 52W:
$0.861
$0.9495
Hookipa Pharma Inc Stock (HOOK) Company Profile
Nome
Hookipa Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta HOOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
0.924 | 0 | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-11-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-03 | Iniziato | Truist | Buy |
| 2020-10-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-19 | Ripresa | H.C. Wainwright | Buy |
| 2019-09-27 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-13 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Hookipa Pharma Inc Borsa (HOOK) Ultime notizie
Ranking HOOKIPA Pharma Inc. among high performing stocks via toolsJuly 2025 Pullbacks & Entry Point Strategy Guides - newser.com
Portfolio Shifts: Can HOOKIPA Pharma Inc sustain its profitabilityAnalyst Downgrade & Free Verified High Yield Trade Plans - khodrobank.com
Can a trend reversal in HOOKIPA Pharma Inc. lead to recoveryJuly 2025 Breakouts & Weekly Setup with High ROI Potential - newser.com
HOOKIPA Pharma Inc.’s volatility index tracking explainedJuly 2025 Levels & Risk Adjusted Swing Trade Ideas - newser.com
Is HOOKIPA Pharma Inc. meeting your algorithmic filter criteriaTrade Signal Summary & Daily Profit Maximizing Tips - newser.com
Aug Intraday: Can HOOKIPA Pharma Inc reach all time highs this yearCPI Data & Risk Controlled Stock Pick Alerts - khodrobank.com
Why HOOKIPA Pharma Inc. is moving todayM&A Rumor & Risk Managed Investment Entry Signals - newser.com
What indicators show strength in HOOKIPA Pharma Inc.Forecast Cut & Weekly Consistent Profit Watchlists - newser.com
How to read the order book for HOOKIPA Pharma Inc.July 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Market Outlook: Is HOOKIPA Pharma Inc stock a smart retirement pickJuly 2025 Earnings & Safe Capital Investment Plans - khodrobank.com
US Market Wrap: How does HOOKIPA Pharma Inc compare to its peersEarnings Overview Summary & Weekly Consistent Profit Watchlists - khodrobank.com
Hedge Fund Bets: Can HOOKIPA Pharma Inc. reach resistance levels soonJuly 2025 Review & Safe Swing Trade Setup Alerts - khodrobank.com
Market Catalysts: Can HOOKIPA Pharma Inc deliver consistent EPS growthEarnings Growth Report & Risk Managed Investment Signals - خودرو بانک
Breakouts Watch: Will HOOKIPA Pharma Inc. stock benefit from M&ALong Setup & Verified High Yield Trade Plans - khodrobank.com
New Highs: Does HOOKIPA Pharma Inc have pricing powerStop Loss & Weekly High Conviction Ideas - khodrobank.com
Earnings Risk: Whats HOOKIPA Pharma Incs historical return2025 Macro Impact & Verified Short-Term Trading Plans - خودرو بانک
What MACD signals say about HOOKIPA Pharma Inc.Weekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale - MSN
Panic Selling: What is HOOKIPA Pharma Incs revenue forecast2025 Trading Recap & AI Powered Trade Plan Recommendations - khodrobank.com
Investor Mood: What is HOOKIPA Pharma Incs revenue forecast2025 Year in Review & Low Drawdown Trading Strategies - خودرو بانک
Smart tools for monitoring HOOKIPA Pharma Inc.’s price action2025 Price Targets & Real-Time Price Movement Reports - newser.com
Published on: 2025-09-15 05:24:42 - newser.com
MACD Signal: Is HOOKIPA Pharma Inc. attractive for institutional investors2025 Technical Overview & Expert Approved Momentum Ideas - خودرو بانک
Can HOOKIPA Pharma Inc. reach all time highs this year2025 Price Action Summary & Growth Focused Entry Reports - خودرو بانک
Analyzing HOOKIPA Pharma Inc. with multi timeframe chartsJuly 2025 Outlook & Daily Volume Surge Signals - newser.com
Full technical analysis of HOOKIPA Pharma Inc. stock2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
Measuring HOOKIPA Pharma Inc.’s beta against major indices2025 Earnings Surprises & Safe Entry Point Alerts - Newser
Backtesting results for HOOKIPA Pharma Inc. trading strategies2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - Newser
How sentiment analysis helps forecast HOOKIPA Pharma Inc.Market Sentiment Review & Free Safe Entry Trade Signal Reports - Newser
Statistical indicators supporting HOOKIPA Pharma Inc.’s strengthPortfolio Value Report & Stock Portfolio Risk Control - Newser
What data driven models say about HOOKIPA Pharma Inc.’s futureSwing Trade & Proven Capital Preservation Tips - Newser
Multi factor analysis applied to HOOKIPA Pharma Inc.2025 Historical Comparison & Verified Short-Term Plans - Newser
Hookipa Pharma Inc Azioni (HOOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
0.09%
Capitalizzazione:
|
Volume (24 ore):